NPC1L1 Inhibitors
4 drugsAbout NPC1L1
NPC1L1, or Niemann-Pick C1-Like 1, is a key protein that mediates intestinal absorption of cholesterol. By controlling cholesterol uptake, NPC1L1 plays a central role in maintaining cholesterol homeostasis. This makes it an important drug target for managing cholesterol levels and related metabolic disorders.
Human genetic studies provide strong validation for NPC1L1 as a therapeutic target, with variants linked to hypercholesterolemia (score 0.82) and metabolic disease (score 0.80). Loss-of-function variants are protective against hypercholesterolemia, supporting inhibition-based therapies. There are also 20 strong eQTL/pQTL signals.
NPC1L1 is targeted by 4 FDA-approved small molecule drugs, including ZETIA, VYTORIN, and NEXLIZET. These drugs are developed by Merck, ESPERION THERAPS INC, and GLENMARK PHARMS LTD, primarily for metabolic indications. The first drug was approved in 2002, and the most recent in 2020.
NPC1L1 Genetic Evidence Strong
NPC1L1 has strong genetic support with a max score of 0.82 linking it to hypercholesterolemia.
Strong genetic support increases the likelihood of clinical success, warranting further investment.
💡 Why inhibition?
- • Loss-of-function variants reduce disease risk (OR < 1)
- • 100% directional consistency across 2 traits
- • Strong signal in phenotype, nutritional or metabolic disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
14 totalGWAS and other genetic studies link NPC1L1 to 14 diseases.
Inhibiting this target may be therapeutic
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for NPC1L1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top NPC1L1 Drugs
Three companies, including Merck and ESPERION THERAPS INC, have approved drugs targeting NPC1L1.
The market is moderately concentrated, suggesting potential for new entrants with differentiated therapies.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| EZETIMIBE AND SIMVASTATIN | ALKEM LABS LTD | 2017 | 6 |
NPC1L1 Drug Modality Landscape
Modalities
Routes of Administration
NPC1L1 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
NPC1L1 Clinical Trials 309 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on NPC1L1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 82 | 74 | 6 | 2 | 93% |
| Phase 2 | 62 | 47 | 8 | 7 | 85% |
| Phase 3 | 87 | 65 | 11 | 11 | 86% |
| Phase 4 | 78 | 49 | 10 | 19 | 83% |
Top Sponsors
By Modality
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved NPC1L1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting NPC1L1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
NPC1L1 Drug Approval Timeline (2002 - 2020)
The approval timeline for NPC1L1-targeting drugs spans 19 years, from 2002 to 2020.
The recent approval of NEXLIZET in 2020 indicates continued interest and potential for further drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 184 (56 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on NPC1L1. A trial counts if an approved drug acting on NPC1L1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.